Guggenheim Securities Expands Healthcare Investment Banking & Advisory Practice Appointments Represent Commitment to Strengthening a Cornerstone of the Firm's Investment Banking Platform PR Newswire NEW YORK, Aug. 8, 2012 NEW YORK, Aug. 8, 2012 /PRNewswire/ -- Guggenheim Partners, LLC ("Guggenheim"), a global diversified financial services firm, today announced the appointments of Stuart Duty, Ron Gerber and Barry Shin to Guggenheim Securities' healthcare investment banking and advisory team. Based in New York, Messrs. Duty, Gerber and Shin join an existing team led by Alan Schwartz, Executive Chairman of Guggenheim Partners, and Ken Springer, Senior Managing Director. "Stuart, Ron and Barry will add significant expertise to our growing healthcare platform," said Mr. Schwartz. "This sector is core to our investment banking business, and their deep industry relationships and experience, especially in equity new issuance and life sciences M&A, will be invaluable as we continue to expand our franchise." With over 20 years of experience in the life sciences sector, Mr. Duty joins as a Senior Managing Director with responsibility for helping build the healthcare practice. Previously, he was Co-Head of Healthcare Investment Banking at Piper Jaffray. Prior to that, Mr. Duty held senior-level positions in healthcare investment banking at Montgomery Securities and Kidder Peabody & Co. Also from Piper Jaffray, Messrs. Gerber and Shin are joining Guggenheim Securities as Managing Director and Vice President, respectively. Together, they have over 25 years experience advising specialty pharmaceutical and biotechnology companies across a range of financing and M&A transactions. "Ron, Barry and I are pleased to join the Guggenheim Securities team," added Mr. Duty. "The firm's accomplishments in the healthcare sector, as well as the steady growth of the entire investment banking franchise, are highly regarded throughout the industry. We look forward to building on the success with new mandates and advisory relationships." Since its launch in 2009, Guggenheim Securities' healthcare investment banking and advisory practice has advised Pfizer on its $2.4 billion sale of Capsugel to KKR and Merck KGaA on its $7 billion acquisition of Millipore, in addition to numerous mid-market transactions. Guggenheim Securities is also building a healthcare-focused sales and trading team, and the firm publishes healthcare market commentary focused on regulatory and legislative issues through its Washington Research Group. About Guggenheim Partners Guggenheim Partners, LLC is a privately held global financial services firm with more than $160 billion in assets under management. The firm provides asset management, investment banking and capital markets services, insurance, institutional finance and investment advisory solutions to institutions, governments and agencies, corporations, investment advisors, family offices and individuals. Guggenheim Partners is headquartered in New York and Chicago and serves clients around the world from more than 25 offices innine countries. For more information about Guggenheim Partners, visit www.guggenheimpartners.com. Contacts: Guggenheim Partners Torie von Alt 212-378-6216 Torie.firstname.lastname@example.org Or Brunswick Group Tripp Kyle / Felipe Ucros / Liz Bruce 212-333-3810 email@example.com SOURCE Guggenheim Partners, LLC Website: http://www.guggenheimpartners.com
Japan August Exports Fall 1.3% on Year Versus Estimate of -2.6%
Guggenheim Securities Expands Healthcare Investment Banking & Advisory Practice
Press spacebar to pause and continue. Press esc to stop.